Markets & Finance

Thomas Weisel Ups Harvard Bioscience to 'Outperform'


Thomas Weisel upgraded Harvard Bioscience (HBIO) to outperform from peer perform.

Analyst Paul Knight says the upgrade is based on: Strong second-quarter operating performance, vs. previous periods; a string of successful acquisition consolidations (Genomic Solutions, Gene Machines, and BioRobotics) that are expanding margins; and, potential growth benefit from improved pharmaceutical demand.

Knight notes second-quarter results marked the best performance in more than a year. He thinks Harvard Bioscience's position in the pharmceutical industry (65% exposure) leverages its business model to benefit from a spending up cycle that's driven by the conclusion of the Pfizer/Pharmacia consolidation. Knight sees 25 cents 2003 earnings per share, 30 cents per share for 2004, and 40 cents per share for 2005.


American Apparel's Future
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Sponsored Financial Commentaries

Sponsored Links

Buy a link now!

 
blog comments powered by Disqus